Cite
Final analysis of a phase II trial using sorafenib for metastatic castration-resistant prostate cancer.
MLA
Aragon-Ching, Jeanny B., et al. “Final Analysis of a Phase II Trial Using Sorafenib for Metastatic Castration-Resistant Prostate Cancer.” BJU International, vol. 103, no. 12, June 2009, pp. 1636–40. EBSCOhost, https://doi.org/10.1111/j.1464-410X.2008.08327.x.
APA
Aragon-Ching, J. B., Jain, L., Gulley, J. L., Arlen, P. M., Wright, J. J., Steinberg, S. M., Draper, D., Venitz, J., Jones, E., Chen, C. C., Figg, W. D., & Dahut, W. L. (2009). Final analysis of a phase II trial using sorafenib for metastatic castration-resistant prostate cancer. BJU International, 103(12), 1636–1640. https://doi.org/10.1111/j.1464-410X.2008.08327.x
Chicago
Aragon-Ching, Jeanny B., Lokesh Jain, James L. Gulley, Philip M. Arlen, John J. Wright, Seth M. Steinberg, David Draper, et al. 2009. “Final Analysis of a Phase II Trial Using Sorafenib for Metastatic Castration-Resistant Prostate Cancer.” BJU International 103 (12): 1636–40. doi:10.1111/j.1464-410X.2008.08327.x.